menu
    • menu
    [{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Sapphire Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"SPX-1009","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Zenith Epigenetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"ZEN-3694","moa":"BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"TumorGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"3","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"15","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Privo Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"AUM LifeTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"TransCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ The Division of Cancer Treatment and Diagnosis"}]

    Find Clinical Drug Pipeline Developments & Deals by The Division of Cancer Treatment and Diagnosis

    Menu

    The Division of Cancer Treatment and Diagnosis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : AUM LifeTech

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI/NIH Grant to Advance Their Lung Cancer Im...

                            Details : AUM LifeTech's FANA Antisense Oligonucleotide (FANA ASO) RNA silencing approach allows efficient and selective targeting of human FOXP3 at the RNA level, in a highly sequence-specific manner.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            August 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : AUM LifeTech

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTX-MC138

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : TransCode Therapeutics

                            Deal Size : $2.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award

                            Details : The SBIR award, supports the continued clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate for the treatment of advanced solid tumors. TTX-MC138 has the potential to produce regression without recurrence in a range of cancers.

                            Product Name : TTX-MC138

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            June 01, 2022

                            Lead Product(s) : TTX-MC138

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : TransCode Therapeutics

                            Deal Size : $2.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Privo Technologies

                            Deal Size : $2.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Soli...

                            Details : The award supports the first-in-man clinical study of Privo’s PRV211 Intraoperative Anti-Cancer Treatment. It is used for all solid tumors to eliminate any remining cancer cells post-surgical resection.

                            Product Name : PRV211

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 25, 2022

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Privo Technologies

                            Deal Size : $2.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : TumorGen

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TumorGen Receives $390K NCI Grant to Counter Metastasis

                            Details : With this funding, the company will test the new technology in lung cancer patients, capturing metastatic cancer cell clusters (MCCCs) in their blood.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : TumorGen

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN-3694,Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Zenith Epigenetics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

                            Details : First clinical Study to Combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer.

                            Product Name : ZEN-3694

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 05, 2020

                            Lead Product(s) : ZEN-3694,Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Zenith Epigenetics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPX-1009

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Sapphire Biotech

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Sapphire Biotech Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Insti...

                            Details : The grant will support the continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (“QSOX1”) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, in...

                            Product Name : SPX-1009

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 11, 2020

                            Lead Product(s) : SPX-1009

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Sapphire Biotech

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selinexor

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Karyopharm Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research

                            Details : The Cooperative Research and Development Agreement will focus on advancing XPOVIO (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, which blocks the cellular protein XPO1.

                            Product Name : Xpovio

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            July 17, 2020

                            Lead Product(s) : Selinexor

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Karyopharm Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Roswell Park Comprehensive Cancer Center

                            Deal Size : $14.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M

                            Details : Prestigious grant will fund 5 clinical trials in patients with 3 cancer types.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            April 06, 2020

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Roswell Park Comprehensive Cancer Center

                            Deal Size : $14.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth